Artelo Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Gorgas Gregory D., was filed 12 Aug 2022.
Since the insiders bought
- -55.5%Entry US$706.32 · Close at T+365 US$314.28
- -1.5%Entry US$3,207.60 · Close at T+365 US$3,159.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,200 shares@ US$4.008.4% of flowCommon StockSEC:0001640334-22-001760:0Canonical exit: 10 Nov 2022 (T+90)
- 1,200 shares@ US$4.038.5% of flowCommon StockSEC:0001640334-22-001706:0Canonical exit: 9 Nov 2022 (T+90)
- 8,500 shares@ US$1.1517.8% of flowCommon StockSEC:0001640334-21-000982:0Canonical exit: 15 Jul 2021 (T+90)
- 4,200 shares@ US$1.2112.4% of flowCommon StockSEC:0001640334-20-001281:0Canonical exit: 13 Aug 2020 (T+90)
- 41,667 shares@ US$1.20100.0% of flowCommon StockSEC:0001640334-20-001029:0Canonical exit: 2 Aug 2020 (T+90)
- 4,167 shares@ US$1.2012.1% of flowCommon StockSEC:0001640334-20-001028:0Canonical exit: 2 Aug 2020 (T+90)
- 17,500 shares0Common StockSEC:0001640334-20-000327:0
- 2,400 shares@ US$2.2112.6% of flowCommon StockSEC:0001640334-19-002181:0Canonical exit: 2 Feb 2020 (T+90)
- 2,600 shares@ US$1.9912.3% of flowCommon StockSEC:0001640334-19-002169:0Canonical exit: 28 Jan 2020 (T+90)
- 2,500 shares@ US$1.9511.6% of flowCommon StockSEC:0001640334-19-002169:1Canonical exit: 29 Jan 2020 (T+90)
- 2,500 shares@ US$2.2813.5% of flowCommon StockSEC:0001640334-19-002169:2Canonical exit: 30 Jan 2020 (T+90)
- 2,600 shares@ US$2.0512.8% of flowCommon StockSEC:0001640334-19-002067:0Canonical exit: 13 Jan 2020 (T+90)
- 2,700 shares@ US$1.9612.7% of flowCommon StockSEC:0001640334-19-002035:0Canonical exit: 9 Jan 2020 (T+90)
13 of 13 declarations
About Artelo Biosciences, Inc.
At Artelo Biosciences, Inc., Gregory D. Gorgas, filed as Pres, CEO, CFO, Treas & Secr, signs 11 of the 13 filings in the record, and every one is a purchase. Overall, 12 purchases total EUR 101,168, median EUR 4,726, without a single sale. The largest purchase is not Gregory D. Gorgas's, though: Connie Matsui, a director, bought EUR 45,854 on May 4, 2020, within a cluster where 2 filers bought EUR 55,142 between May 4 and May 15, 2020. Gregory D. Gorgas bought EUR 8,165 on April 16, 2021 and EUR 5,109 on November 1, 2019.
Peter Michael O'Brien, a holder of more than 10%, has one filing, which is not a purchase. The 13 filings are published from October 11, 2019 to August 12, 2022: 6 in 2019, 4 in 2020, one in 2021 and 2 in 2022.
Read moreShow less
This US company listed on Nasdaq is valued at USD 1.4 million, and insiders hold 0.1% of it. The median publication delay is 1 day. Across 10 purchases with a 90-day return, the stored median is -9.8%, with 20% positive (past results on record, not a forecast). No filing falls within the last twelve months.
